Orexo AB (ORX) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Your line is muted. Welcome to the conference call. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answer session, participants are able to ask questions by dialing star five on their telephone keypad. Now I will hand the conference over to the speakers. Please go ahead. Good afternoon, everyone on the call. So I'm pleased here to report our first quarter of 2026. Together with me today, I have Fredrik Jastein, who will go through the financial results of the report. As you know, this is the first report that we have without SobSol, and that, of course, has a significant impact on the way that we are presenting the data and also the length of the presentation, as we don't have the commercial asset with us anymore. So a short summary of where we are right now. We sold, and this has been a quarter which has been one of the most intensive from a work perspective from most of us together with the end of last quarter due to the transition of software. As you know, we sold that on the last day of 2025. But of course, most of the transition activities have been been for a while. Thank you. We have in the end, during the quarter, we have, of course, a lot of these activities have led to a reduction of cash position because we're paying a lot of fees. We redeemed our corporate bond, and in the end, we have a reduction in cash position. We are on the balance sheet right now, which is actually attributable to Dexel because we're running their accounts receivables. All in all, I think the transition with SobSol has been very successful. It has been very smooth. There's been no interruptions in the sale of SobSol in the market in the US. collaboration with Dexcel have been running smoothly, and we're quite pleased...